跳至主要内容
临床试验/ACTRN12619000791134
ACTRN12619000791134终止1 期

A pilot trial of Exendin PET scanning in metastatic castrate resistant prostate cancer to demonstrate GLP1 receptor positive disease

Mark S Stein Pty Ltd0 个研究点目标入组 4 人开始时间: 2019年5月28日最近更新:
适应症

试验速览

阶段
1 期
状态
终止
发起方
入组人数
4

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Male

入选标准

  • 1) Metastatic castrate resistant prostate cancer (mCRPC)
  • 2) A history of radical prostatectomy
  • 3) More than one lesion on a PSMA PET scan performed in The Department of Cancer Imaging of The Peter MacCallum Cancer Centre, Melbourne, Australia

排除标准

  • Date of most recent PSMA PET scan more than 2 weeks ago
  • Known allergy or adverse reaction to Exenatide, other GLP-1 agonist or meta-Cresol
  • Creatinine clearance less than 30mL/minute and/or dialysis dependent renal failure
  • Type 1 diabetes
  • Severe gastrointestinal disease
  • Use of warfarin
  • Past history of pancreatitis
  • New York Heart Association Class IV dyspnoea
  • Intercurrent severe depression
  • Factors that would make it impractical to have radioactive urine
  • Variables that in the opinion of a member of the research team preclude the opportunity for informed consent and/or adherence to study protocol by a potential participant.

研究者

发起方
Mark S Stein Pty Ltd

相似试验